Fig 1: Western blot analysis of RANKL and OPG expression in the hind ankle (A) and serum biomarker analysis (B) in different groups of rats. ?? p < 0.01 vs. CON, **p < 0.01 vs. CIA, # p < 0.05 vs. CIA+PDN (n = 7).
Fig 2: Effect of catalpol on osteogenic differentiation and calcification of MC3T3-E1 cells treated by high glucose. Expression of OPG and RANKL levels was measured during catalpol treatment under high glucose condition by Western blot. Quantitated levels of OPG, RANKL, and the ratio of two proteins were statistically evaluated. The data were expressed as the mean ± SD. **p < 0.01 vs. control and ## p < 0.01 and # p < 0.05 vs. model.
Fig 3: Histological and immunohistochemical analyses of ankle joints in different groups of rats. Paraffin sections of the ankle joint were prepared for H&E staining and immunohistochemical staining of TNF-a, RANKL, and OPG. The expression of biomarkers was evaluated by semiquantitative analysis with Image-Pro Plus software. ?? p < 0.01 vs. CON, **p < 0.01 vs. CIA, # p < 0.05 vs. CIA+PDN (n = 7).
Fig 4: In the co-culture system, melatonin upregulates the expression of OPG and decreases the expression and secretion of RANKL. The expression (A) and secretion (B) of RANKL and OPG in MC3T3-E1 cells cultured for 7 days with RANKL (30 ng/mL) and M-CSF (10 ng/mL) with high glucose in the presence of varying concentrations (0.1 or 1 µmol/L) of melatonin. Data are represented as the mean ± SD (n = 3). **p < 0.01. OPG, Osteoprotegerin; RANKL, receptor activator of nuclear factor ? B ligand; M-CSF, macrophage colony-stimulating factor
Fig 5: Activation of the Wnt/ß-catenin signaling pathway alters the expression levels of OPG, TRAP, DKK1, Wnt2 and ß-catenin proteins in the jaw. *P<0.05, compared with the sham group; #P<0.05, compared with the OP group; ^P<0.05, compared with the miR-146a group. OPG, osteoprotegerin; TRAP, tartrate-resistant acid phosphatase; DKK1, dickkopf1; sham, sham group; OP, osteoporosis group; miR-146a-A, miR-146a antagonist group; DKK2-C2, Wnt activator group; miR + E, miR-146a antagonist + Wnt inhibitor group.
Supplier Page from Abcam for Anti-Osteoprotegerin antibody